Cardiac‐related rehospitalisation · heart failure associated with central sleep apnoea
PAP therapy showed no clear difference in cardiac‐related rehospitalisation compared with usual care (low certainty).
1 finding from 1 review
QoL · heart failure associated with central sleep apnoea
2 findings from 1 review
Adverse events · heart failure associated with central sleep apnoea
1 finding from 1 review
Menopause‐specific quality of life (quality of life) · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Effect on later sexual function · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Sexual distress (sexual distress) · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Vasomotor symptoms (vasomotor) · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Measures of psychosocial factors · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Physical symptoms (physical) · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Sexual symptoms (sexual) · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
Body image · female BRCA carriers post‐risk‐reducing surgery
1 finding from 1 review
ICU/HDU admission ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Symptom score at 10 days. Measured on a 7‐point scale (0 to 6) ; lower score denotes fewer symptoms · acute asthma exacerbation
1 finding from 1 review
All adverse events · acute asthma exacerbation
Antibiotics showed no clear difference in all adverse events compared with placebo or usual care (low certainty).
1 finding from 1 review
Serious adverse events Duration 3 days to 3 weeks · acute asthma exacerbation
Antibiotics showed no clear difference in serious adverse events Duration 3 days to 3 weeks compared with placebo or usual care (low certainty).
1 finding from 1 review
Mortality ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Length of hospital stay · acute asthma exacerbation
1 finding from 1 review
Relapse ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
PEFR (GIV) Duration 10 days · acute asthma exacerbation
1 finding from 1 review
Outcomes (end of treatment) · people with dementia (all resided in institutional settings)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found